Minerva Neurosciences reported a GAAP net loss of $293.4 million for the year ended December 31 2025, a sharp increase from the $1.4 million loss recorded in 2024. The company’s cash, cash equivalents and restricted cash rose to $82.4 million, up from $21.5 million at the end of 2024, giving it a substantial runway to fund its clinical program.
Research and development expenses for 2025 were $5.8 million and general and administrative costs were $9.3 million. The large jump in net loss is largely attributable to non‑cash charges related to convertible preferred stock and warrants issued in connection with the company’s financing, which were not present in the prior year.
On October 23 2025, Minerva completed a private‑placement financing that raised $80 million in cash. The proceeds are earmarked for the Phase 3 confirmatory trial of roluperidone for negative symptoms of schizophrenia and to support a subsequent New Drug Application resubmission. The financing structure also provides up to an additional $80 million if all Tranche A warrants are exercised, and an extra $40 million if Tranche B warrants are exercised upon achieving the primary endpoint of the Phase 3 trial in the second half of 2027.
The company’s board has aligned the trial design with FDA expectations, following a Complete Response Letter issued in February 2024 that required a redesign of the study. The confirmatory trial is scheduled to begin in the second quarter of 2026, with topline efficacy data expected in the second half of 2027.
Management noted that the $80 million upfront proceeds and the exercise proceeds from the Tranche A warrants would provide sufficient funds to complete the Phase 3 trial and resubmit the NDA ahead of a potential U.S. launch, if approved. "Strengthened by the recent financing and our general alignment with the U.S. Food and Drug Administration (“FDA”) on trial design, we are working towards initiation of the confirmatory Phase 3 trial with roluperidone for the treatment of negative symptoms of schizophrenia in the second quarter," said Dr. Remy Luthringer, Chairman and CEO. "With the $80 million upfront proceeds and the exercise proceeds from the Tranche A warrants, we anticipate sufficient funds to complete the Phase 3 trial and resubmission of the New Drug Application (“NDA”) ahead of the launch of roluperidone in the United States, if approved." "This does not happen very often, but here we have all the alignments necessary in order to move forward," added Luthringer.
The financing structure carries a significant dilution risk, as the exercise of warrants could increase the number of shares outstanding. With no product sales to date, Minerva’s business model relies entirely on the success of roluperidone, making the Phase 3 trial and subsequent regulatory approval critical to the company’s future prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.